The document from Pfizer shows that a third dose of the vaccine raises levels of neutralising antibodies and sparked no major safety concerns.
A panel of independent experts are set to meet on Friday to debate whether people should get boosters of the Pfizer -BioNTech COVID-19 shot.
Story continuesThe document from Pfizer shows that a third dose of the vaccine raises levels of neutralizing antibodies, which are critical virus-killing proteins that play a key role in our immune response, and sparked no major safety concerns.Protection from Pfizer's vaccine wanes over time
The booster-shot debate has gained urgency due to the spread of the Delta variant, which carries certain mutations that make the virus far more contagious. Those mutations have also made the vaccines, which were developed against the original strain of the virus, somewhat less effective, particularly at stopping asymptomatic or mild infections.
Pfizer presented results from at least eight studies showing protection from the vaccine wanes over time and that a booster could help rebuild that immunity. A study from Kaiser Permanente showed protection against infection fell from 88% in the first month after the second dose to 47% after more than five months. Other analyses from Pfizer's clinical trial, the CDC, and Israel support the idea that protection against infection declines over time. headtopics.com
Pfizer's documents included a new analysis of its massive late-stage clinical study, breaking out the data to focus just on the Delta variant. While there was not a statistically meaningful difference between Delta infections and other sequenced variants, the vaccine dropped to 53% effectiveness at preventing infection four months after vaccination.
The shot is still good at preventing hospitalizations and deathsReal-world results still show that protection against severe disease, hospitalization, and death remain quite high, contributing to the debate over whether or not boosters shots are now needed.
While some data from Israel has suggested that protection wanes, other studies from the CDC have shown that protection against hospitalization and death remains high.Pfizer also did not include data from randomized trials showing boosters increase protection, nor does the company have data suggesting how long-lasting booster protection may be.
Instead, Pfizer presented data from two small clinical trials that combined to test a third dose on about 330 volunteers who were mostly younger adults. This research showed the extra dose increased the levels of neutralizing antibodies, which is a critical element of the immune response. But scientists have not yet determined the exact level of antibodies that correlates with protection. headtopics.com
The FDA said it had not reviewed or verified the data from a number of these observational studies, including data from Israel.The agency did state that COVID-19 vaccines are still protecting against severe disease and death in the US, and it confirmed the conclusions from Pfizer's small clinical trials for boosters, which showed they raised antibody levels and didn't carry any major safety concerns.
Booster, second-dose side effects are similarThe FDA documents also provided the most detailed look yet at theside-effect profile for booster shots. Previously, Pfizer has described the safety of booster shots in press releases as generally in line with the second dose.
In Pfizer's study of about 300 younger volunteers, the most common side effects were injection site pain (83%), fatigue (64%), headache (48%), muscle pain (39%), and chills (29%).Those rates are roughly in line with what trial volunteers experienced after the second dose, and the vast majority of theses side effects were mild or moderate in intensity. The most common severe side effect was fatigue, which about 5% of participants reported.
The expert panel will listen to presentations from officials from the CDC, the UK, Israeli public-health officials, Pfizer, and FDA reviewers. The FDA also did not release the questions it will ask the group to vote on.While the FDA typically follows the recommendations of its expert panels, it isn't required to do so. If the FDA authorizes booster doses, the CDC's own independent group of advisors would then debate and vote on recommendations for how boosters should be rolled out. headtopics.comRead more: Yahoo Singapore »
Household members dining-in in groups of 5, team sports could be allowed if weekly Covid-19 infection rate falls: Lawrence Wong
Covid-19: 804 new locally transmitted cases; 2 more clusters discovered at nursing homesI really wonder how all the nursing homes are getting infected.I am sure their SOPs are very strict considering the people living in all these homes are aged. The virus seems to know where to “hit” where SOPs are vulnerable..KTVs,Fishery Port,Market/Food Centre,Airports,Malls…
Sinovac to supply Singapore with additional 101,000 doses of Covid-19 vaccineSINGAPORE — Sinovac will supply Singapore with another 101,000 doses of its Covid-19 vaccine, the company said on Wednesday (Sept 15).
I gave birth to my first child just before COVID-19 worsened in MalaysiaSeems easier to protect baby Max when he was still inside of me. This article, I gave birth to my first child just before COVID-19 worsened in Malaysia, originally appeared on Coconuts, Asia's leading alternative media company.
Commentary: The Delta variant has upended the East Asia COVID-19 modelEast Asian approaches built on elimination and containment have proved difficult to pursue in the face of the Delta variant and growing socio-economic costs, says a political scientist. B
About 3,200 vaccinated seniors first to receive Covid-19 booster shots0.2 percent of Americans have died from virus-related causes. Not 'with' covid anymore, but virus related causes - any virus. Are you still believing this crap, scare story? Surely even the intellectually challenged must by now be doubting this...?
See the very good dogs tasked with sniffing out COVID-19 at the Miami airportCobra and One Betta will sniff the masks of each employee at a security checkpoint to detect the virus through their sweat and breath.